News – Page 2 – Alligator Bioscience

2026-03-27

Regulatory

The Nomination Committee’s proposals regarding the Board of Directors for the Annual General Meeting in Alligator Bioscience AB (publ)

The Nomination Committee of Alligator Bioscience AB (publ) (“Alligator Bioscience”) proposes re-election of Hans-Peter Ostler an ...

2026-03-26

Regulatory

Lund, Sweden, 26 March 2026 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Annual Report for 2025, as well ...

2026-03-20

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, J ...

2026-03-18

Lund, Sweden – 18 March 2026 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing ...

2026-03-16

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2026-03-10

Lund, Sweden – 10 March 2026 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing ...

2026-03-02

Lund, Sweden – 2 March 2026 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today comments on the announcement by Shanghai Henl ...

2026-02-27

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2026-02-12

Regulatory

Rights issue completed: Approximately SEK 91 million (gross) raised in December, strengthening financial position with additional warrant up ...